Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
RSV, Pfizer
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and marketed by US pharma giant Pfizer, the vaccine is now authorized for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine,
FDA Clears Pfizer RSV Vaccine for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine
Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59
The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste
Pfizer announces FDA approval of Abrysvo
Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
pharmaphorum
3d
Pfizer seeks to overturn three RSV vaccine patents held by GSK
Already competing to bring the first
vaccine
against respiratory syncytial virus (
RSV
) to market,
Pfizer
and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...
12d
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
21h
on MSN
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
NK troops in RU confirmed
Linked to E. coli outbreak
Arlington visit records order
Dodgers legend dies
Trespassing charge upheld
2 US troops injured in raid
MO court upholds release
First father-son duo in NBA
Lake Erie toxic algae study
To close 150 locations
Veteran film producer dies
Funds corruption guilty plea
US fines American Airlines
FDA approves RSV vaccine
Giant ‘ghost’ fish spotted
DOJ alleges racial bias
GA election rules appeal
To appear on Rogan podcast
FAA finalizes safety rules
Brain stimulation study
SK mulls arms for Ukraine
Raises US growth forecast
Same-day pharmacy delivery
Six indicted for fraud in Ohio
2025 Medicare changes
US semiconductor tax credit
Hospitals' IV fluid shortage
Ordered to hand over assets
Reveals 2025 tax brackets
Feedback